RS50368B - Levodopa/karbidopa/entakapon farmaceutski preparat - Google Patents

Levodopa/karbidopa/entakapon farmaceutski preparat

Info

Publication number
RS50368B
RS50368B YUP-925/01A YUP92501A RS50368B RS 50368 B RS50368 B RS 50368B YU P92501 A YUP92501 A YU P92501A RS 50368 B RS50368 B RS 50368B
Authority
RS
Serbia
Prior art keywords
entacapone
levodopa
carbidopa
pharmaceutically acceptable
composition
Prior art date
Application number
YUP-925/01A
Other languages
English (en)
Serbian (sr)
Inventor
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Kari Vahervuo
Matti Virkki
Original Assignee
Orion Corporation,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50368(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation, filed Critical Orion Corporation,
Publication of YU92501A publication Critical patent/YU92501A/sh
Publication of RS50368B publication Critical patent/RS50368B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
YUP-925/01A 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat RS50368B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (2)

Publication Number Publication Date
YU92501A YU92501A (sh) 2004-09-03
RS50368B true RS50368B (sr) 2009-11-10

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-925/01A RS50368B (sr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat

Country Status (42)

Country Link
US (2) US6500867B1 (enExample)
EP (1) EP1189608B1 (enExample)
JP (2) JP4204783B2 (enExample)
KR (1) KR100905428B1 (enExample)
CN (1) CN1168440C (enExample)
AR (1) AR033796A1 (enExample)
AT (1) ATE245417T1 (enExample)
AU (1) AU765932B2 (enExample)
BG (1) BG65364B1 (enExample)
BR (2) BR0011867A (enExample)
CA (1) CA2378469C (enExample)
CO (1) CO5180579A1 (enExample)
CZ (2) CZ303010B6 (enExample)
DE (1) DE60004052T2 (enExample)
DK (1) DK1189608T3 (enExample)
EA (1) EA004503B1 (enExample)
EE (1) EE05473B1 (enExample)
ES (1) ES2203495T3 (enExample)
FI (1) FI109453B (enExample)
FR (1) FR2797587A1 (enExample)
GE (1) GEP20043314B (enExample)
HK (1) HK1047040B (enExample)
HR (1) HRP20020088B1 (enExample)
HU (1) HU230395B1 (enExample)
IL (1) IL146807A (enExample)
IT (1) ITMI20001450A1 (enExample)
ME (1) ME00520B (enExample)
MX (1) MXPA01013167A (enExample)
MY (1) MY127685A (enExample)
NO (2) NO330260B1 (enExample)
NZ (1) NZ515780A (enExample)
PE (1) PE20010399A1 (enExample)
PL (1) PL197818B1 (enExample)
PT (1) PT1189608E (enExample)
RS (1) RS50368B (enExample)
SI (1) SI1189608T1 (enExample)
SK (1) SK286451B6 (enExample)
TR (1) TR200103763T2 (enExample)
TW (1) TWI241187B (enExample)
UA (1) UA75047C2 (enExample)
WO (1) WO2001001984A1 (enExample)
ZA (1) ZA200109868B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US8772346B2 (en) * 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
ATE534382T1 (de) * 2008-02-06 2011-12-15 Wockhardt Ltd Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
US20110229566A1 (en) 2008-08-22 2011-09-22 Yatendra Kumar Gupta Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
JP5718937B2 (ja) 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
JP5774610B2 (ja) 2010-03-04 2015-09-09 オリオン コーポレーション パーキンソン病の治療方法
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
DK2640358T3 (en) * 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112013027219A2 (pt) * 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
US9126988B2 (en) 2011-12-13 2015-09-08 Bial—Portela & Ca, S.A. Intermediate for preparing a catechol-O-methyltransferase inhibitor
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
HUE056006T2 (hu) * 2013-03-13 2022-01-28 Neuroderm Ltd Kombináció Parkinson-kór kezelésére
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CN109689036B (zh) * 2016-07-11 2026-06-19 康特拉医药股份有限公司 用于治疗早晨运动不能的脉冲药物输送系统
ES2895054T3 (es) 2016-08-18 2022-02-17 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Fórmula de comprimido antiparkinson con perfil de disolución mejorado
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
NO20110090L (no) 2002-02-25
CZ20014636A3 (cs) 2002-05-15
FI991485A0 (fi) 1999-06-30
PE20010399A1 (es) 2001-04-10
NO330260B1 (no) 2011-03-14
CA2378469A1 (en) 2001-01-11
NO20016203L (no) 2002-02-25
US6797732B2 (en) 2004-09-28
SK19232001A3 (sk) 2002-06-04
ES2203495T3 (es) 2004-04-16
SK286451B6 (sk) 2008-10-07
HUP0202273A3 (en) 2002-11-28
CZ303010B6 (cs) 2012-02-29
JP4204783B2 (ja) 2009-01-07
HK1047040A1 (en) 2003-02-07
JP4885896B2 (ja) 2012-02-29
CN1358090A (zh) 2002-07-10
EE200100716A (et) 2003-02-17
HUP0202273A2 (en) 2002-10-28
SI1189608T1 (en) 2004-04-30
NO20016203D0 (no) 2001-12-18
EP1189608B1 (en) 2003-07-23
TWI241187B (en) 2005-10-11
JP2003503454A (ja) 2003-01-28
AU5830600A (en) 2001-01-22
EA200200106A1 (ru) 2002-06-27
PL197818B1 (pl) 2008-04-30
HK1047040B (zh) 2005-04-29
DK1189608T3 (da) 2003-11-10
CA2378469C (en) 2009-10-06
EA004503B1 (ru) 2004-04-29
AR033796A1 (es) 2004-01-07
FI109453B (fi) 2002-08-15
PT1189608E (pt) 2003-12-31
WO2001001984A1 (en) 2001-01-11
MY127685A (en) 2006-12-29
HRP20020088A2 (en) 2005-10-31
BR0011867A (pt) 2002-03-05
NZ515780A (en) 2004-06-25
FI991485L (fi) 2000-12-31
YU92501A (sh) 2004-09-03
EP1189608A1 (en) 2002-03-27
BRPI0011867B1 (pt) 2019-01-08
BG65364B1 (bg) 2008-04-30
ZA200109868B (en) 2003-05-28
GEP20043314B (en) 2004-02-10
ATE245417T1 (de) 2003-08-15
DE60004052T2 (de) 2004-04-15
FR2797587A1 (fr) 2001-02-23
EE05473B1 (et) 2011-10-17
BRPI0011867B8 (pt) 2021-05-25
KR20020010155A (ko) 2002-02-02
AU765932B2 (en) 2003-10-02
TR200103763T2 (tr) 2002-04-22
MXPA01013167A (es) 2002-07-02
IL146807A (en) 2006-10-05
HRP20020088B1 (hr) 2007-05-31
ITMI20001450A0 (it) 2000-06-28
ITMI20001450A1 (it) 2001-12-28
BG106251A (en) 2002-08-30
PL352775A1 (en) 2003-09-08
CN1168440C (zh) 2004-09-29
JP2008156373A (ja) 2008-07-10
US6500867B1 (en) 2002-12-31
HU230395B1 (hu) 2016-04-28
KR100905428B1 (ko) 2009-06-30
UA75047C2 (en) 2006-03-15
DE60004052D1 (de) 2003-08-28
CZ304416B6 (cs) 2014-04-23
US20030017201A1 (en) 2003-01-23
CO5180579A1 (es) 2002-07-30
ME00520B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
JP4885896B2 (ja) レボドパ／カルビドパ／エンタカポン医薬製剤
RU2485947C2 (ru) Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
IL161491A (en) Tamsulosin tablets
KR20150126900A (ko) 데페라시록스의 경구 제제
JP2014196334A (ja) クエチアピンを含む徐放性医薬組成物
KR20150044670A (ko) 제어방출되는 프로피온산 계열의 약제학적 조성물
CN103860550A (zh) 左旋多巴/卡比多巴/罗匹尼罗药物制剂